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suggest that state-of-the-art 3.0 T is equivalent to 1.5 T 
in the assessment of focal liver lesions and diffuse liver 
disease. Therefore, further technical improvements are 
needed in order to fully exploit the potential of higher 
field strength.
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Core tip: The editorial focuses on potential advantages 
and drawbacks related to the use of 3.0 Tesla (T) 
magnets in liver imaging. Current clinical applications 
are discussed, with special emphasis on the comparison 
with 1.5 T. If careful optimization is performed, state-
of-the-art 3.0 T is equivalent to 1.5 T. Further technical 
improvements are needed in order to fully exploit the 
potential of higher field strength.
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MOVING TOWARDS 3.0 TESLA?
Because of limited availability and costs, magnetic 
resonance imaging (MRI) of the liver is usually performed 
as a problem-solving tool after inconclusive prior ultra-
sound and/or computed tomography (CT). However, 
MRI is, per se, the imaging modality of choice for the 
detection and characterization of focal liver lesions[1], 
owing to superior contrast resolution and the “all-in-one” 
information provided by hepatospecific contrast agents 
such as gadobenate dimeglumine (Gd-BOPTA) and 
gadoxetic acid (Gd-EOB-DTPA). Less defined is the role 
of MRI in assessing diffuse liver disease, as exemplified 
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Abstract
An ever-increasing number of 3.0 Tesla (T) magnets are 
installed worldwide. Moving from the standard of 1.5 
T to higher field strength implies a number of potential 
advantage and drawbacks, requiring careful optimization 
of imaging protocols or implementation of novel hard-
ware components. Clinical practice and literature review 
EDITORIAL
Submit a Manuscript: http://www.wjgnet.com/esps/
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
DOI: 10.4254/wjh.v7.i15.1894
1894 July 28, 2015|Volume 7|Issue 15|WJH|www.wjgnet.com
World J Hepatol  2015 July 28; 7(15): 1894-1898
ISSN 1948-5182 (online)
© 2015 Baishideng Publishing Group Inc. All rights reserved.
3.0 Tesla magnetic resonance imaging: A new standard in 
liver imaging?
by current, intensive research on different techniques 
aimed to quantify fibrosis, steatosis or iron overload[2]. 
1.5 Tesla (T) systems still represent the technical 
standard for abdominal MRI[3]. Nonetheless, the use of 
ultra-high field strength is a major focus in liver imaging, 
given the ever-increasing number of new 3.0 T magnets 
installed worldwide for research and clinical practice. One 
might wonder whether 3.0 T might become the new 
standard, as occurred in the past when moving from 
lower field strength to 1.5 T. In theory, 3.0 T magnets 
have the capability to provide better image quality as 
the base for improved diagnostic performance. This is 
because doubling the field strength (almost) doubles 
signal-to-noise ratio[4], that is the quantity of signal 
made available from the patient in order to build MRI 
images. Exceeding signal can be converted into better 
image detail (higher spatial resolution) and/or faster 
acquisition (higher temporal resolution), as well as more 
efficient fat suppression and better lesion conspicuity 
because of improved lesion-to-liver contrast after 
gadolinium administration[5]. Both conventional imaging 
and functional techniques such as diffusion-weighted 
imaging (DWI), dynamic contrast-enhanced MRI and 
spectroscopy may benefit from the above changes. 
CHALLENGES RELATED TO 3.0 T
Despite theoretical promises, the available evidence 
shows some disappointing results when comparing 
3.0 T vs 1.5 T, especially for T2-weighted imaging. For 
example, two studies[6,7] on patients with chronic liver 
disease showed that radiologists perceive equal or lower 
image quality at higher field strength. The explanation 
for such a discrepancy is that the transition from 1.5 T 
to 3.0 T harbours technical challenges at serious risk 
of impairing the gain in signal-to-noise ratio. Major 
concerns in liver imaging are related to three factors[5]. 
First, changes in tissue relaxation times affect image 
contrast, at a larger degree on T1-weighted Spoiled 
Gradient Echo images. This can make the detection of 
focal lesions, fibrosis or steatosis more challenging at 3.0 
T[8]. Second, the radiofrequency (RF) power deposition 
to the patient significantly increases, especially for Turbo 
Spin Echo (TSE)-designed T2-weighted sequence using 
a large number of RF pulses to generate image contrast. 
RF power deposition represents the energy administered 
to the patient to obtain signal back, and is measured as 
specific absorption rate (SAR). Unfortunately, strategies 
to reduce 3.0 T-related increase in SAR frequently occur 
at the expense of the gain in signal. Third, image quality 
can be degraded by the so called standing wave artefact, 
resulting from inhomogeneous RF deposition due to 
interactions between RF waves and the patients’ body[5]. 
Standing wave artefact consists of zones of gross signal 
drop affecting T2-weighted images at a serious extent[9], 
usually in correspondence of the left liver lobe (Figure 1). 
Despite there is no definite correlation with body mass 
index or body fat content, the artefact prevails in larger 
patients, being characteristically exacerbated by the 
presence of ascites[5,8,9]. 
How to overcome technical limitations? In a study by 
von Falkenhausen et al[10], image quality at 3.0 T was 
found equivalent to 1.5 T using comparable acquisition 
parameters, emphasizing that the implementation of 
standard 1.5 T MRI protocols on 3.0 T magnets requires 
careful optimization and/or new technical solutions 
to exploit the potential of higher field-strength. While 
problems in T1 contrast and SAR are faced by imple-
menting proper sequence design[11,12], standing wave 
artefacts should be more consistently prevented by 
intervening on the magnet hardware[13], that is by 
implementing more than one conventional RF source 
in order to independently correct phase and amplitude 
of the RF pulses for patient-induced B1-inhomogeneity. 
Studies using new-generation 3.0 T systems with dual-
source parallel RF transmission[9,13,14] showed significant 
qualitative and quantitative image improvement for TSE-
based T2-weighted imaging, which is the real “Achilles 
heel” of liver MRI at 3.0 T. Results with and without 
hardware implementation are conflicting in terms of 
better lesions detectability[9,14]. However, dual-source 
systems are reasonably the best state-of-the-art solution 
to minimize standing wave effect in obese individuals 
and/or patients with ascites, in whom lesions can be 
missed because of degraded image quality. 
ADVANTAGES OF USING 3.0 T
On the bright side, 3.0 T was proven to provide superior 
post-gadolinium image quality using 1.5 T-equivalent 
volumetric fat-saturated Gradient-Echo T1-weighted 
imaging[7,12]. This is in accordance with the experience in 
many centers using 3.0 T, including our Institution (Figure 
2). Lee et al[15] suggested that the quality of the dynamic 
study is further improved when replacing conventional 
fat suppression technique at 3.0 T (spectrally adiabatic 
inversion recovery) with the Dixon approach. These 
results have potential diagnostic impact in terms of 
better detection and characterization of smaller lesions, 
especially in late arterial phase or hepatobiliary phase[8]. 
One might wonder whether superior quality of post-
contrast imaging is just a matter of the sequence used 
or rather the type and dose of contrast medium. Indeed, 
the T1 relaxation time of the liver in vivo increases of 
about 41% at 3.0 T compared to 1.5 T[5], translating into 
a theoretical increase in contrast differences using an 
equivalent dose of gadolinium-based contrast agents[16].
A study by Kim et al[17] supports this assumption. Com-
paring arterial late phases acquired in same individuals 
with the standard dose of gadoxetic acid (0.025 mmol/kg) 
and half dose of gadobenate dimeglumine (0.05 mmol/
kg), the Authors found higher relative enhancement 
of the liver at 3.0 T rather than 1.5 T, for both contrast 
agents (19.4% vs 11.4% and 33.4% vs 18.9%, 
respectively). Alternatively, one can achieve adequate 
image contrast at 3.0 T using less contrast medium, 
as shown by de Campos et al[18] with a quarter dose of 
gadobenate dimeglumine (0.025 mmol/kg). Potential 
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clinical consequences are better lesions detectability and 
reduction of the risk of nephrogenic systemic fibrosis 
in selected patients. However, image contrast after the 
administration of gadolinium chelates is a matter of 
complex interactions. Not surprisingly, studies in vitro 
and in vivo[16] are concordant in showing comparable 
contrast enhancement of the liver between 1.5 T and 3.0 
T at equivalent concentrations, regardless of the dose. In 
summary, it is difficult to quantify the impact of contrast 
agent properties in determining superior image quality of 
3.0 T contrast-enhanced studies.
DIAGNOSTIC PERFORMANCE OF 3.0 T 
SYSTEMS
The ever-increasing diffusion of magnets for everyday 
clinical practice, and rise in publications of radiological 
studies performed with 3.0 T suggest that higher field 
strength is at least equivalent to 1.5 T in diagnostic 
terms. Unfortunately, there is paucity of prospective 
works comparing 1.5 T and 3.0 T on an intraindividual 
basis. In a study on 35 patients who underwent both 
1.5 T and 3.0 T with a superparamagnetic iron oxide 
contrast agent, Chang et al[19] showed equivalent 
accuracy in assessing malignant focal liver lesions, with 
lower image quality at higher field strength. Only a 
few papers focus on hepatocellular carcinoma (HCC) 
and colorectal cancer metastases. In a 3.0 T standing-
alone study by Lee et al[15], the Authors found an overall 
accuracy in the detection of HCC with gadoxetic acid 
similar to 1.5 T (mean AUC 0.95). Interestingly, two 
different studies[20,21] compared the detection of HCC 
between 3.0 T MRI and triple-phase multidetector CT 
(MDCT), showing equivalent high accuracy, though MRI 
was able to detect more lesions on a per-patient basis 
(2.7 vs 2.3)[20] and performed better for smaller HCC (≤ 
1 cm in size)[21]. It is difficult to compare these results 
with those obtained in other studies with lower field 
strength, e.g., by Akai et al[22], who showed a trend to 
a better performance of gadoxetic-acid-enhanced 1.5 
T MRI vs 64-raw MDCT. Based on the experience in my 
Institution, 3.0 T MRI is at least equivalent to 1.5 T, being 
helpful in assessing cases in which the number of lesions 
is crucial to plan the treatment (e.g., liver transplant), 
as well in the scenarios of lesion characterization and 
detection of recurrence. Concerning colorectal cancer 
metastases, 3.0 T showed excellent detection rates 
combining gadoxetic acid and DWI, with AUCs of 
0.915-0.937 at ROC analysis[23]. Compared to MDCT, 
3.0 T MRI showed better performance, though without 
statistical significance[24], especially in the detection of 
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Figure 1  T2-weighted imaging with 3.0 Tesla. In the absence of dedicated technical solutions, T2-weighted images at 3.0 Tesla (T) (A) are at risk of typical artefacts 
(namely standing-wave artefacts) causing signal drop-out over the field of view, especially left liver lobe. Focal liver lesions might be masked accordingly. The artefact 
is not present at 1.5 T (B).
A B
A B
Figure 2  T1-weighted post-contrast imaging at 3.0 Tesla. Compared to 1.5 Tesla (T) (A), post-contrast images acquired on 3.0 T magnets (B) show sharper 
details, as exemplified in this patient with chronic liver disease showing multiple artero-portal shunts. 
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especially in those patients in whom improved dynamic 
study is expected to provide “key” information, such as 
detection and characterization of hypervascular lesions 
(e.g., HCC). 
In summary, if the new standard in liver imaging 
should be undoubtedly better than the older one, state-
of-the-art 3.0 T is far from representing it. However, 
ongoing technical improvements are expected to exploit 
all the potential advantages inherent to higher field 
strength, suggesting that 3.0 T candidates for the new 
standard in liver imaging in the next future.
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